WA-VIRTUOZZO
Virtuozzo , the alternative cloud platform leader, announced today that it will preview at CloudFest 2022 two never-before-seen solutions designed to help service providers bring to market modern cloud-based solutions that answer long-ignored market needs. The products are the PaaS-focused Virtuozzo Application Platform for WordPress and Virtuozzo Hybrid Server Lite. Framing their value proposition, Virtuozzo executives will deliver two keynote presentations outlining the current industry trends and landscape shaping the need for those services. The sessions will also introduce practical strategies for service providers to integrate and deploy the new solutions in ways that help them increase competitive positioning while growing their business.
Attendees can visit Virtuozzo, a platinum event sponsor, at Stand C01 throughout the show (March 22 – 24) in Europa-Park, Germany. Additionally, a special on-site promotion will give service providers six months free licensing for key solutions showcased during the conference.
Virtuozzo: Bringing Cloud to All
As a company, Virtuozzo has strategically evolved over the last several years to fill a polarizing void in the cloud enablement market. The most common paths to the cloud leverage hyperscaler or enterprise-centric platforms that are generally inflexible, cost-prohibitive, and too complex for non-specialized end users to manage. This puts many businesses, particularly small- to medium-sized ones, at a disadvantage. Which is where Virtuozzo comes in.
“There was an inherent promise in the beginning that cloud would be easy. Accessible to all. In reality, that is not how things panned out,” said Alex Fine, CEO, Virtuozzo. “Virtuozzo is solving that problem through collaborative partnerships with service providers that empower them to become full-service, alternative cloud providers.”
Virtuozzo develops and delivers the most comprehensive cloud platform stack purpose built for service providers. That infrastructure allows services providers to quickly carve out a wide portfolio of cloud services that are easy to use, easy to manage, and easy to scale. This frees them to then focus on areas where they can strongly differentiate, from the delivery of unique products and skills to high-touch customer support.
Virtuozzo Keynote Presentations
The Service Provider Landscape in 2022: Where is the Low-Hanging Fruit?
March 22 at 3:45 PM CET
Carlos Rego, Virtuozzo’s VP of Strategic Development, addresses the roller coaster ride that has been the experience of hosters, MSPs and cloud providers over the past decade. He provides expert perspective on the complex landscape they currently operate in, how the industry is evolving, and how these service providers can strategically grow their businesses without overly taxing their operations.
WordPress Hosting? It’s Time to Grow Up.
March 23 at 4:40 PM CET
In his second presentation, Carlos Rego will introduce viable revenue-generating opportunities surrounding the booming $500B+ WordPress economy. With new PaaS capabilities via Virtuozzo Application Platform for WordPress targeting business-critical WordPress sites, service providers can strengthen their businesses while helping modernize an enormous ecosystem that can be argued is antiquated today.
Schedule a Meeting
To meet with a Virtuozzo team member on site, contact info@Virtuozzo.com .
About Virtuozzo
Virtuozzo (www.virtuozzo.com ) provides the leading alternative cloud platform for service providers, enabling them to sell cloud services that are more accessible, more affordable and easier to use than hyperscaler solutions. The company’s legacy includes developing the first commercially available container technology and being a major contributor to numerous virtualization and open-source projects for more than 20 years. Today, Virtuozzo cloud solutions are used by more than 700 Cloud Service Providers, Managed Service Providers and Hosting Providers in 80 countries. Virtuozzo is based in Schaffhausen, Switzerland, and has more than 320 employees across the U.S., UK, Europe, and Asia-Pacific.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005472/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom